Added to YB: 2026-07-30
Pitch date: 2026-07-27
CAI [bullish]
Caris Life Sciences, Inc.
-0.95%
current return
Author Info
No bio for this author
Company Info
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
Market Cap
$4.4B
Pitch Price
$15.74
Price Target
N/A
Dividend
N/A
EV/EBITDA
28.73
P/E
-8.68
EV/Sales
4.42
Sector
Biotechnology
Category
growth
Caris Life Sciences: The Quiet Founder Trying to Win the Holy Grail of Oncology
CAI: Molecular diagnostics/AI TechBio in oncology, 13yr proprietary genomics dataset moat. FY25 rev ~$812M (+97%), 65% gross margin, adj-EBITDA/FCF positive but GAAP still loss-making. Net cash, founder-owner (built $7.5B AdvancePCS). ~4.5x fwd sales, fair P/E 30, ~35% IRR base case. Risk: ASP-driven growth decelerating to ~25%. Free option on Caris Detect early-detection test (60% sensitivity, 99% specificity). Small speculative position; down 60% post-IPO.
Read full article (12 min)